Merck’s $1.85 Billion Acquisition of Pandion Therapeutics

Troutman Pepper Hamilton Sanders LLP advised Pandion Therapeutics, Inc. on the deal.Pandion Therapeutics, Inc., a clinical-stage biotechnology company developing novel therapeutics for those living with autoimmune diseases, has agreed to be acquired by Merck in a transaction valued at approximately $1.85 billion.

Pandion has created a pipeline of potential treatments that target the body’s natural immune regulatory responses with the aim to achieve better clinical outcomes for patients living with autoimmune diseases, such as ulcerative colitis and numerous others.

Troutman Pepper Partner Daniel M. Scolnick (Picture) advised Pandion on all patent issues related to the deal.

Involved fees earner: Daniel Scolnick – Troutman Pepper Hamilton Sanders LLP;

Law Firms: Troutman Pepper Hamilton Sanders LLP;

Clients: Pandion Therapeutics, Inc.;

Author: Martina Bellini